Rocket Pharmaceuticals Inc (NAS:RCKT)
$ 22.23 0.3 (1.37%) Market Cap: 2.02 Bil Enterprise Value: 1.69 Bil PE Ratio: 0 PB Ratio: 4.56 GF Score: 39/100

Rocket Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 10:40PM GMT
Release Date Price: $17.22 (-0.46%)
Unidentified Analyst

The second day of the BOA Health Care Conference. My name is [Alister Murray]. I'm associate on the large biotechnology team here at Bank of America Merrill Lynch. I have the pleasure today of introducing Rocket Pharmaceuticals. From the company, we have Gaurav Shah, President and CEO of Rocket. Gaurav, I hand over to you.

Gaurav Shah
Rocket Pharmaceuticals, Inc. - CEO, President & Director

Thanks for the introduction. It's good to see everyone. I will try to do about 10 or 12 minutes of going through slides pretty rapidly. Q&A is always my favorite part. So for those with questions, please ask them.

So Rocket Pharma -- how do I do this in 10 minutes relatively rapidly? Rocket Pharma started about 3.5 years ago, based out of New York City, with the idea that we wanted to address gene therapy through a multi-platform approach. So we're working with both in vivo AAV gene therapy and ex vivo lentiviral-based gene therapy. So we're multi-platform gene therapy company, and I think the essence of the philosophy here is that we want to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot